Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, VitaNova Life Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VitaNova Life Sciences Days Payable vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, VitaNova Life Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where VitaNova Life Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
VitaNova Life Sciences's Days Payable for the fiscal year that ended in Apr. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VitaNova Life Sciences (VNOV) has a Days Payable of 9.55 as of Apr. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on VitaNova Life Sciences and its competitors. This is 74% below median its historical median of 36.07. Over the past decade, VitaNova Life Sciences' Days Payable has ranged from 20.50 to 106.85.
Is VitaNova Life Sciences' Days Payable too high?
VitaNova Life Sciences' current Days Payable of 9.55 is 74% below median its 10-year median of 36.07. Over the past 10 years, this metric has ranged from a low of 20.50 to a high of 106.85. The Medical Distribution industry median Days Payable is 79.11. VitaNova Life Sciences' value of 9.55 is 87.9% below this industry median. Overall, VitaNova Life Sciences has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does VitaNova Life Sciences' Days Payable compare to HKPD and COSM?
VitaNova Life Sciences' Days Payable of 9.55 can be compared against companies in the Medical Distribution industry. The industry median Days Payable is 79.11. VitaNova Life Sciences' value of 9.55 is 87.9% below this benchmark. Historically, VitaNova Life Sciences' own Days Payable has ranged from 20.50 to 106.85 over the past decade. While the company's 10-year median is 36.07 vs. the industry median of 79.11, VitaNova Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Distribution company?
The median Days Payable among Medical Distribution companies is 79.11, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VitaNova Life Sciences's current Days Payable of 9.55 is 87.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on VitaNova Life Sciences and its competitors. For the Medical Distribution industry, the median Days Payable is 79.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VitaNova Life Sciences's current Days Payable is 9.55, which is 74% below median its own 10-year median of 36.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VitaNova Life Sciences stock overvalued right now?
VitaNova Life Sciences (VNOV) has a current Days Payable of 9.55. The stock's GF Value™ is $5.95, compared to a current price of $1.38 — trading 76.8% below its estimated fair value. The current Days Payable is 9.55, which is 74% below median its 10-year median of 36.07 and 87.9% below the Medical Distribution industry median of 79.11. VitaNova Life Sciences' overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For VitaNova Life Sciences (VNOV), the current Days Payable is 9.55 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VitaNova Life Sciences (VNOV) Overvalued in 2026?
Based on GuruFocus' analysis, VitaNova Life Sciences stock appears to be undervalued.
The current stock price of $1.38 is trading 76.8% below its estimated GF Value™ of $5.95.
Key valuation signals for VNOV:
Days Payable: 9.55 (74% below median its 10-year median of 36.07)
GF Value™: $5.95 vs. price of $1.38 (76.8% below fair value)
Industry Position: 87.9% below the Medical Distribution median
No single metric tells the full story. See the VNOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VitaNova Life Sciences Corp, formerly Yijia Group Corp provides business consulting services to domestic and international customers. The Company provides consulting services to its clients with regards to funding and other financial matters.The company's operating segments are The consulting services Segment mainly provides consulting advisory services in management, business, accounting and finance; and the Healthcare Segment mainly provides healthcare products and health consultation services to customers. The sale and distribution of healthcare products, such as Nicotinamide Riboside capsules, has only one performance obligation under the fixed-fee arrangements. and the majority of its revenue generates from Sales of healthcare products.
51GF Score
Get the complete analysis for VNOV
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VNOV has been successfully added to your 
